A Review of AI-Based Radiomics and Computational Pathology Approaches in Triple-Negative Breast Cancer: Current Applications and Perspectives
Breast cancer is among the most prevalent and lethal tumors globally. Approximately 20% of all breast cancers are classified as triple-negative (TNBC). Triple-negative breast cancer (TNBC) is generally linked to a worse prognosis compared to other breast cancer subtypes. Conventional cytotoxic chemotherapy is the standard treatment due to its aggressiveness and resistance to hormone therapy; nevertheless, this approach is not consistently effective, and a significant proportion of patients experience recurrence.